Eli Lilly
U.S. pharma major behind Mounjaro and Zepbound — the biggest beneficiary of the obesity-drug boom.
Coverage of Eli Lilly is holding steady : 4 signals on the latest tracked day, down 56% from its three-week baseline of 9, across 3 domains (unchanged from a week ago). That makes it the #228 most-covered of the 348 concerns we track.
What’s changed
6 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.
- GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly’s Weight-Loss Boom Hitting an Insurance Wall? · 24/7 Wall St. · 2026-08-29
- Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here’s Why. · 24/7 Wall St. · 2026-08-24
- Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial - smallcaps.com.au · KRAS Mutation Research (Google News) · 2026-08-04
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - Eli Lilly and Company · KRAS Mutation Research (Google News) · 2026-08-03
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes | Eli Lilly and Company · Reddit r/biotech · 2026-08-29 · usually covers Biotech Pharma
- Anyone work at the vaccine division at Eli Lilly? · Reddit r/biotech · 2026-08-27 · usually covers Biotech Pharma
What the reporting says
Across 44 tracked stories from 23 outlets, reporting on Eli Lilly most often describes regulatory approvals (11), acquisition (1), public statements (1).
It shows up alongside KRAS (10), FDA (15), Bristol Myers Squibb (8), GLP-1 (8), Lung Cancer (8).
Two steps out: AI (through FDA, 15 shared stories on the weaker link); Cder (through FDA, 15 shared stories on the weaker link); Clinical Trials (through FDA, 15 shared stories on the weaker link); Colorectal Cancer (through FDA, 15 shared stories on the weaker link).
Tracked since May 6, with coverage on 20 separate days — concentrated in Kras Research and Auto.